WHO joins agencies in beefing up inspections of API facilities

The World Health Organization (WHO) is joining an effort to extend the reach of regulatory inspections of API facilities and reduce duplication by sharing resources, InPharm reports. The effort was started by the US, Europe and Australia, allowing each to rely on inspections by the others to better use existing resources. The FDA, EMA and the Australian Therapeutic Goods Administration (TGA) can accept a report, ask regulators of one of the participants to expand an inspection or they can hold joint inspections. A recent report on the effort noted the WHO has joined through its Prequalification of Medicines program and that other entities agreeing to the requirements also may be allowed to participate. Story | Report

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.